JP2007145809A - Endurance improver - Google Patents
Endurance improver Download PDFInfo
- Publication number
- JP2007145809A JP2007145809A JP2006272791A JP2006272791A JP2007145809A JP 2007145809 A JP2007145809 A JP 2007145809A JP 2006272791 A JP2006272791 A JP 2006272791A JP 2006272791 A JP2006272791 A JP 2006272791A JP 2007145809 A JP2007145809 A JP 2007145809A
- Authority
- JP
- Japan
- Prior art keywords
- resveratrol
- leaf extract
- grape leaf
- aging
- endurance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 claims abstract description 68
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 65
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 60
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 60
- 235000013305 food Nutrition 0.000 claims abstract description 41
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 33
- 210000003205 muscle Anatomy 0.000 claims abstract description 33
- 230000007659 motor function Effects 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 86
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 84
- 235000021283 resveratrol Nutrition 0.000 claims description 82
- 229940016667 resveratrol Drugs 0.000 claims description 82
- 230000032683 aging Effects 0.000 claims description 41
- 230000009471 action Effects 0.000 claims description 33
- 230000037149 energy metabolism Effects 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 22
- 230000009467 reduction Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000003387 muscular Effects 0.000 claims description 14
- 206010028289 Muscle atrophy Diseases 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000020763 muscle atrophy Effects 0.000 claims description 13
- 201000000585 muscular atrophy Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000001629 suppression Effects 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000002431 foraging effect Effects 0.000 claims description 2
- 241000219095 Vitis Species 0.000 claims 18
- 230000008859 change Effects 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 abstract description 47
- RUOKEYJFAJITAG-CUYWLFDKSA-N resveratroloside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 RUOKEYJFAJITAG-CUYWLFDKSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000006872 improvement Effects 0.000 description 19
- 235000013361 beverage Nutrition 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- 239000002775 capsule Substances 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000009395 breeding Methods 0.000 description 8
- 230000001488 breeding effect Effects 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 241000219094 Vitaceae Species 0.000 description 6
- 241001593968 Vitis palmata Species 0.000 description 6
- 235000002532 grape seed extract Nutrition 0.000 description 6
- 235000021021 grapes Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 229940087603 grape seed extract Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 description 5
- 235000014101 wine Nutrition 0.000 description 5
- -1 carnitine compound Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 241001512058 Vitis labrusca x Vitis vinifera Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XLAIWHIOIFKLEO-UHFFFAOYSA-N (E)-4-<2-(4-hydroxyphenyl)ethenyl>phenol Natural products C1=CC(O)=CC=C1C=CC1=CC=C(O)C=C1 XLAIWHIOIFKLEO-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-UPHRSURJSA-N Cis-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C/C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UPHRSURJSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000252206 Cypriniformes Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-CENDIDJXSA-N Piceid Natural products OC[C@@H]1O[C@@H](Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)[C@H](O)[C@H](O)[C@H]1O HSTZMXCBWJGKHG-CENDIDJXSA-N 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 241000375392 Tana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000004282 Vitis labrusca Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- HSTZMXCBWJGKHG-OUUBHVDSSA-N piceide Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-OUUBHVDSSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 235000018991 trans-resveratrol Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本発明は、広義の運動に対する持久力向上剤、抗疲労剤、筋力向上剤、運動機能向上剤、及び老化抑制剤に関する。 The present invention relates to endurance improvers, anti-fatigue agents, muscle strength improvers, motor function improvers, and aging inhibitors for exercise in a broad sense.
近年、交通手段の発達や情報・通信技術の発展に伴い、運動が不足している。運動不足は、持久力の低下や筋力の低下等、運動機能の低下の原因となり、その後のQOLに重大な悪影響をもたらすと考えられる。 In recent years, with the development of transportation means and the development of information and communication technology, there is a lack of exercise. Lack of exercise is considered to cause a decrease in motor function such as a decrease in endurance and a decrease in muscle strength, and a serious adverse effect on the subsequent QOL.
加齢に伴う筋萎縮や持久力、筋力の低下は運動機能を低下させ、寝たきり等の原因となる。また筋萎縮や筋力の低下が原因で起こる日常動作中の転倒、及びそれに伴う骨折は高齢者における主要な寝たきりの原因となっている。 Muscle atrophy, endurance, and a decrease in muscle strength associated with aging decrease motor function and cause bedridden. In addition, falls during daily movements caused by muscle atrophy and weakness, and the accompanying fractures are the main cause of bedridden in elderly people.
したがって、日常の生活機能を改善、維持し、健康寿命を延伸するためには、日頃から運動機能を維持または高めておくこと、また老化に伴う運動機能の低下を抑制することが重要である。 Therefore, in order to improve and maintain daily life functions and extend a healthy life span, it is important to maintain or enhance motor functions on a daily basis and to suppress a decrease in motor functions associated with aging.
運動機能を向上させるには、運動トレーニングを行うことが適切であるといえるが、忙しさのため十分な運動をする時間がとれない人や、運動してもすぐに疲労してしまい、継続して運動できない人も多いのが現状である。また、高齢者においては、適度な運動を実践する、あるいはリハビリテーションを実践する等が運動能力低下を防ぐ手段として用いられているが、モチベーションの維持の困難さや怪我の恐れもあり、現実的にはなかなか難しく、より効果的な方法が望まれている。 It may be appropriate to perform exercise training to improve motor function, but people who cannot get enough exercise time due to their busyness or who get tired immediately after exercising will continue. Many people are unable to exercise. In elderly people, practicing moderate exercise or practicing rehabilitation is used as a means to prevent a decline in motor ability. However, in reality, it may be difficult to maintain motivation or injuries. It is quite difficult and a more effective method is desired.
これらの問題を解決する一つの手段として、持久力や筋力などの運動機能向上作用や、抗疲労作用を有する食品成分を日常的に摂取することが考えられる。例えば、本発明者らは、カテキンを摂取することによる持久力向上効果を見出した(特許文献1)。その他の持久力向上効果を有する成分として報告されている例は、サンザシ抽出物(特許文献2)や霊芝成分(特許文献3)、プロアントシアニジン及びリコペン(特許文献4)等が挙げられる。また、抗疲労作用を有する成分の例としては、コエンザイムQ10、カルニチン配合物(特許文献5)やグルタミンペプチド(特許文献6)等が挙げられる。 As one means for solving these problems, it is conceivable to ingest daily food components having an action function improving action such as endurance and muscle strength and an anti-fatigue action. For example, the present inventors have found an endurance improvement effect by ingesting catechin (Patent Document 1). Examples of other reported components having endurance enhancing effects include hawthorn extract (Patent Document 2), ganoderma component (Patent Document 3), proanthocyanidins and lycopene (Patent Document 4). Examples of the component having anti-fatigue action include coenzyme Q10, a carnitine compound (Patent Document 5), a glutamine peptide (Patent Document 6), and the like.
また、運動能力を調節しうる成分として、例えば、シスチンおよびテアニンによる老化防止(特許文献7)、果実ポリフェノールによる筋萎縮抑制(特許文献8)、リコピンによる筋蛋白分解抑制(特許文献9)、カルボキシル基を2つ以上有する有機酸またはその塩類を有効成分とした運動能力低下抑制(特許文献10)、アスタキサンチン及び/またはそのエステルによる疲労予防剤(特許文献11)、プロアントシアニジンによる筋萎縮抑制剤及び運動能力向上剤(特許文献12、特許文献13)等が開示されている。しかしながら、実際の老化に伴う持久力、筋力、エネルギー代謝の低下や筋萎縮に対する効果は検討されていないのが現状である。 In addition, as components that can control exercise ability, for example, aging prevention by cystine and theanine (Patent Document 7), muscle atrophy suppression by fruit polyphenol (Patent Document 8), muscle protein degradation suppression by lycopene (Patent Document 9), carboxyl Inhibition of athletic ability decrease using an organic acid having two or more groups or a salt thereof as an active ingredient (Patent Document 10), an anti-fatigue agent using astaxanthin and / or its ester (Patent Document 11), a muscle atrophy inhibitor using proanthocyanidins, and An athletic performance improver (Patent Literature 12, Patent Literature 13) and the like are disclosed. However, at present, the effects on endurance, muscle strength, energy metabolism decrease and muscle atrophy associated with actual aging have not been studied.
レスベラトロールは、ブドウやその加工品であるワイン、ピーナッツ等に含まれるポリフェノール成分で、その食経験は豊富である。レスベラトロールは、抗癌作用(非特許文献1)や抗動脈硬化作用(非特許文献2)等の作用を示すほか、Sirと呼ばれる分子を介する寿命延長作用(非特許文献3)等が報告されている。また、高脂血症予防・治療(特許文献14)や脳性・加齢性疾患の予防または治療(特許文献15)において有用であることが開示されている。
一方、赤ブドウ葉エキスは、古くから静脈不全の治療薬としての使用が伝統的に知られており、赤ブドウ葉抽出物による血液循環改善法(特許文献16)や慢性静脈不全の治療法(特許文献17)が開示されている。
Resveratrol is a polyphenol component contained in grapes and their processed wines, peanuts, etc., and has a rich dietary experience. Resveratrol exhibits actions such as anticancer action (Non-Patent Document 1) and anti-arteriosclerosis action (Non-Patent Document 2), and also reports a life extension action via a molecule called Sir (Non-Patent Document 3). Has been. It is also disclosed that it is useful in the prevention and treatment of hyperlipidemia (Patent Document 14) and the prevention or treatment of cerebral and age-related diseases (Patent Document 15).
On the other hand, red grape leaf extract has been traditionally known for use as a therapeutic agent for venous insufficiency for a long time. A method for improving blood circulation using red grape leaf extract (Patent Document 16) and a method for treating chronic venous insufficiency ( Patent document 17) is disclosed.
しかし、レスベラトロールやブドウ葉抽出物が持久力をはじめとする運動能力、疲労に対して与える影響及び老化に伴う持久力やエネルギー代謝の低下に及ぼす影響については、これまで全く知られていない。
本発明は、安全性が高く優れた持久力向上作用、抗疲労作用、運動機能向上作用、エネルギー代謝活性化作用、筋力向上作用、老化抑制作用を示す医薬品、医薬部外品及び食品を提供することに関する。 The present invention provides pharmaceuticals, quasi-drugs, and foods that are highly safe and have excellent endurance-improving action, anti-fatigue action, motor function-improving action, energy metabolism-activating action, muscle strength-improving action, and anti-aging action About that.
本発明者らは、身体機能向上において有効な成分の探索を行った結果、食経験が豊富で安全性が高い天然物素材の中から、レスベラトロールやブドウ葉抽出物に持久力向上作用、抗疲労作用、運動機能向上作用、エネルギー代謝活性化作用、筋力向上作用、並びに老化に伴う持久力低下抑制作用、筋萎縮抑制作用、エネルギー代謝低下抑制作用及び筋力低下抑制作用の効果があり、持久力向上剤、筋力向上剤、運動機能向上剤、抗疲労剤、老化抑制剤として有用であることを見出した。また、本発明者らはレスベラトロール及び/又はブドウ葉抽出物が老化に伴う持久力低下抑制効果、筋力低下抑制効果、エネルギー代謝低下抑制効果、筋萎縮抑制効果を有し、老化抑制剤として有用であることを見出した。 As a result of searching for an effective component in improving physical function, the present inventors, among natural materials with abundant dietary experience and high safety, resveratrol and grape leaf extract have an effect of improving endurance, Anti-fatigue action, motor function improvement action, energy metabolism activation action, muscular strength improvement action, endurance reduction suppression action due to aging, muscle atrophy suppression action, energy metabolism reduction suppression action and muscular strength reduction suppression action It was found useful as a strength improver, muscle strength improver, motor function improver, anti-fatigue agent, and antiaging agent. In addition, the present inventors have resveratrol and / or grape leaf extract have an endurance reduction inhibitory effect, muscular strength reduction inhibitory effect, energy metabolism reduction inhibitory effect, muscle atrophy inhibitory effect accompanying aging, and an aging inhibitor I found it useful.
すなわち、本発明は、下記1)〜16)の発明に係るものである。
1)レスベラトロール及び/又はブドウ葉抽出物を有効成分とする持久力向上剤。
2)レスベラトロール及び/又はブドウ葉抽出物を有効成分とする抗疲労剤。
3)レスベラトロール及び/又はブドウ葉抽出物を有効成分とする運動機能向上剤。
4)レスベラトロール及び/又はブドウ葉抽出物を有効成分とするエネルギー代謝活性化剤。
5)レスベラトロール及び/又はブドウ葉抽出物を有効成分とする筋力向上剤。
6)レスベラトロール及び/又はブドウ葉抽出物を有効成分とする老化抑制剤。
7)レスベラトロール及び/又はブドウ葉抽出物を含有し、持久力向上作用を有することを特徴とし、持久力向上のために用いられる旨の表示を付した食品。
8)レスベラトロール及び/又はブドウ葉抽出物を含有し、抗疲労作用を有することを特徴とし、抗疲労のために用いられる旨の表示を付した食品。
9)レスベラトロール及び/又はブドウ葉抽出物を含有し、運動機能向上作用を有することを特徴とし、運動機能向上のために用いられる旨の表示を付した食品。
10)レスベラトロール及び/又はブドウ葉抽出物を含有し、エネルギー代謝活性化作用を有することを特徴とし、エネルギー代謝活性化のために用いられる旨の表示を付した食品。
11)レスベラトロール及び/又はブドウ葉抽出物を含有し、筋力向上作用を有することを特徴とし、筋力向上のために用いられる旨の表示を付した食品。
12)レスベラトロール及び/又はブドウ葉抽出物を含有し、老化抑制作用を有することを特徴とし、老化抑制のために用いられる旨の表示を付した食品。
13)持久力向上剤の製造のためのレスベラトロール及び/又はブドウ葉抽出物の使用。
14)抗疲労剤の製造のためのレスベラトロール及び/又はブドウ葉抽出物の使用。
15)運動機能向上剤の製造のためのレスベラトロール及び/又はブドウ葉抽出物の使用。
16)エネルギー代謝活性化剤の製造のためのレスベラトロール及び/又はブドウ葉抽出物の使用。
That is, the present invention relates to the inventions 1) to 16) below.
1) Endurance improver containing resveratrol and / or grape leaf extract as an active ingredient.
2) An anti-fatigue agent comprising resveratrol and / or grape leaf extract as an active ingredient.
3) A motor function improver comprising resveratrol and / or grape leaf extract as an active ingredient.
4) An energy metabolism activator comprising resveratrol and / or grape leaf extract as an active ingredient.
5) A muscle strength improver comprising resveratrol and / or grape leaf extract as an active ingredient.
6) An aging inhibitor containing resveratrol and / or grape leaf extract as an active ingredient.
7) A food containing resveratrol and / or grape leaf extract, characterized by having an endurance-improving action, and labeled as being used for improving endurance.
8) A food containing resveratrol and / or grape leaf extract, having an anti-fatigue action, and labeled as being used for anti-fatigue.
9) A food containing resveratrol and / or grape leaf extract, characterized by having an effect of improving motor function, and labeled to be used for improving motor function.
10) A food containing resveratrol and / or grape leaf extract, characterized by having an energy metabolism activating action, and labeled as being used for energy metabolism activation.
11) A food containing resveratrol and / or grape leaf extract, characterized by having a muscular strength-improving action, and labeled to be used for improving muscular strength.
12) A food containing resveratrol and / or grape leaf extract, characterized by having an anti-aging effect, and labeled as being used for anti-aging.
13) Use of resveratrol and / or grape leaf extract for the production of endurance enhancers.
14) Use of resveratrol and / or grape leaf extract for the manufacture of anti-fatigue agents.
15) Use of resveratrol and / or grape leaf extract for the production of a motor function enhancer.
16) Use of resveratrol and / or grape leaf extract for the production of an energy metabolism activator.
本発明の持久力向上剤、抗疲労剤、運動機能向上剤、エネルギー代謝活性化剤、筋力向上剤、老化抑制剤は、運動及び日常の動作及び労働を含む広義の運動に対する持久力向上、抗疲労、運動機能向上、エネルギー代謝活性化、及び筋力向上効果を発揮する食品、医薬品、並びに老化に伴い生じる持久力低下、筋萎縮、エネルギー代謝低下、筋力低下を抑制する効果を発揮する食品、医薬品としても有用である。本発明のこれらの剤はレスベラトロール及び/又はブドウ葉抽出物を有効成分とするものであり、食経験が豊富で副作用が少なく、安全性が高い。 The endurance improver, anti-fatigue agent, exercise function improver, energy metabolism activator, muscle strength improver, and anti-aging agent of the present invention are used to improve endurance against a broad sense of exercise including exercise and daily movement and labor, Foods and pharmaceuticals that exhibit fatigue, motor function improvement, energy metabolism activation, and muscle strength improvement effects, and foods and pharmaceuticals that exhibit effects of suppressing endurance reduction, muscle atrophy, energy metabolism reduction, and muscle strength reduction caused by aging It is also useful. These agents of the present invention contain resveratrol and / or grape leaf extract as an active ingredient, have abundant food experience, have few side effects, and are highly safe.
本発明にかかるレスベラトロール(Resveratrol)は、3,4',5-Trihydroxy-stilbeneを意味し、trans−レスベラトロール、cis−レスベラトロール及びそれらの混合物が包含される。本発明においてはこれらの化合物のうち、少なくとも一種が使用される。また、本発明のレスベラトロールは、配糖体(Piceid等)であっても良い。 Resveratrol according to the present invention means 3,4 ′, 5-Trihydroxy-stilbene, and includes trans-resveratrol, cis-resveratrol and mixtures thereof. In the present invention, at least one of these compounds is used. Moreover, the resveratrol of this invention may be a glycoside (Piceid etc.).
本発明におけるレスベラトロールは、有機化学的又は微生物を用いて合成した高純度品の他、ブドウや落花生、ピーナッツ、及びイタドリ等のタデ科植物等のレスベラトロールを含有する天然物から抽出し、適宜精製して用いることができる。また、レスベラトロールを含有する植物、微生物、各種食品の抽出物や部分精製物、加工品を用いてもよい。また、それらの抽出物や部分精製物、加工品から単離したレスベラトロールを用いることも出来る。 The resveratrol in the present invention is extracted from a natural product containing resveratrol such as grapes, peanuts, peanuts, and tadaceae plants such as pits, in addition to high-purity products synthesized using organic chemistry or microorganisms. Can be used after appropriately purifying. In addition, plants, microorganisms, various food extracts, partially purified products, and processed products containing resveratrol may be used. Moreover, resveratrol isolated from those extracts, partially purified products, and processed products can also be used.
天然物としてはブドウ、イタドリが好ましい。
ブドウは、ヨーロッパブドウ(Vitis vinifera)とアメリカブドウ(Vitis labrusca)に分類することができ、そのいずれでもよいが、ヨーロッパブドウが好ましい。
ブドウの種類としては、具体的にはデラウエア、巨峰、甲州、ピオーネ、マスカット、シュナンブラン、グレナッシュ、マタロ、ミュラーテュルガウ、トレッビアーノ、ベリーA、カベルネソービニオン、メルロー、ピノノアール、カベルネフラン、シラー、シャルドネ、ソービニヨンブラン、セミヨン、ガメイ、リースリング、アリゴテ、ミュスカデル、ソーヴィニョン、フォルブランシュ、ミュスカデ、シュナン、グロロー、ピノー・ドーニス、ピノ・ムニエ、ゲヴュルツトラミネール、ピノ・グリ、シルヴァネール、プールサール、サヴァニャン、ジャケール、モンドーズ、ルーセット、カリニャン、サンソー、クレレット、グルナッシュ・ノワール、ムルヴェードル、ユニ・ブラン、ニエルチオ、スキアカレッロ、ヴェルマンチノ、マルサンヌ、ルーサンヌ、ヴィオニエ、ブールブーラン、マカブー、モーザック、タナ、コロンバール、ラン・ドヴ・レル、マルベック、プティ・マンセン、グロ・マンセン、プティ・ヴェルド、サンジョヴェーゼ、ナビオロ、バーベラ、ドルチェット、カリニェナ、ガルナーチャ、モナストレル、テンプラニーニョ等が挙げられる。
As natural products, grapes and Japanese knotweed are preferable.
Grapes can be classified into European grapes ( Vitis vinifera ) and American grapes ( Vitis labrusca ), either of which may be preferred, but European grapes are preferred.
Specific types of grapes include Delaware, Kyoho, Koshu, Pione, Muscat, Chenam Blanc, Grenache, Mataro, Müller Thurgau, Trebbiano, Berry A, Cabernet Sauvignon, Merlot, Pinot Noir, Cabernet Franc, Schiller, Chardonnay, Sauvignon Blanc, Semillon, Gamay, Riesling, Alligote, Muscadelle, Sauvignon, Forblanc, Muscade, Chenin, Gloro, Pinault Dornis, Pinot Meunier, Gewurztraminer, Pinot Gris, Silvaner, Poolsar, Savanyan, Jacquard , Mondoze, Rouset, Carignan, Sansault, Clerette, Grenache Noir, Mourvedre, Uni Blanc, Nielcio, Skia Carello, Vermancino, Rousanne, Rousanne, Viognier, Bourbouran, Macaboo, Mozac, Tana, Colombar, Ran Dove Rel, Malbec, Petit Mansen, Gro Mansen, Petit Verd, Sangiovese, Naviolo, Barbera, Dolce, Carignena, Garnacha , Monastrel, tempranino and the like.
抽出物としては、ブドウ果実、ブドウ葉又はブドウに由来する物からの抽出物等が挙げられ、ブドウ葉抽出物の場合には特に赤ブドウ葉抽出物が好ましく、ヨーロッパブドウ(Foliae Vitis vinifera L.)の赤ブドウ葉抽出物が特に好ましい。ブドウに由来する物としては、例えばブドウジュース、ワイン、ジュースやワイン製造時の残渣、ジュースやワイン濃縮物等が挙げられる。
抽出は、例えば、レスベラトロールがブドウの果皮や葉に多く含まれていることから、当該部位を、水や熱水、アルコール水、有機溶剤等を用いて抽出する一般的な抽出方法が採用できる。
また、レスベラトロールは、ブドウジュース、ワイン、これらの濃縮物又は濃縮乾固した固形物中にも含まれているので、それらを用いることもできる。この場合、これら製造時に発生するブドウの残渣をそのまま用いるか、それから有機溶剤/水等により抽出することもできる。
上記レスベラトロールの抽出に用いられる有機溶剤としては、エタノール等のアルコールが好ましく、特にエタノールが好ましい。
Examples of the extract include an extract from a grape fruit, grape leaf, or a product derived from grape, and in the case of a grape leaf extract, a red grape leaf extract is particularly preferable, and European grape ( Foliae Vitis vinifera L. ) Red grape leaf extract is particularly preferred. Examples of the product derived from grapes include grape juice, wine, juice and residue produced during wine production, juice and wine concentrate.
For extraction, for example, because resveratrol is abundant in grape skins and leaves, a general extraction method that uses water, hot water, alcoholic water, organic solvents, etc., is adopted. it can.
Moreover, since resveratrol is contained also in grape juice, wine, these concentrates, or the solid substance concentrated to dryness, they can also be used. In this case, the grape residue generated during the production can be used as it is, or can be extracted with an organic solvent / water or the like.
As the organic solvent used for the extraction of the resveratrol, alcohol such as ethanol is preferable, and ethanol is particularly preferable.
また、イタドリは、根に多くのレスベラトロールを含むことから、当該部位を上記と同様な一般的な抽出方法により得られるイタドリ抽出物を用いるのが好ましい。 In addition, since the Japanese knotweed contains a lot of resveratrol in its roots, it is preferable to use a knotweed extract obtained by the same general extraction method as that described above.
本発明にかかるレスベラトロール及び/又はブドウ葉抽出物は、後記実施例に示されるように、持久力向上作用、抗疲労作用、筋力向上作用、運動機能向上作用、エネルギー代謝活性化作用、また、老化抑制作用、具体的には老化によって生じる持久力低下抑制作用、筋萎縮抑制作用、エネルギー代謝低下抑制作用、筋力低下抑制作用を有する。従って、レスベラトロール及び/又はブドウ葉抽出物は、持久力向上剤、抗疲労剤、運動機能向上剤、エネルギー代謝活性化剤、筋力向上剤及び老化抑制剤(以下、「持久力向上剤等」とする。)として使用することができ、さらにこれら剤を製造するために使用することができる。持久力向上剤等は、持久力向上、抗疲労、筋力向上、運動機能向上、エネルギー代謝活性化、老化抑制の各効果を発揮する、ヒト若しくは動物用の医薬品、医薬部外品、食品として使用可能である。また、レスベラトロール及び/又はブドウ葉抽出物は、運動不足者や中高年者、ベッドレスト者における持久力向上、抗疲労、運動機能向上、エネルギー代謝活性化、筋力向上又は老化抑制をコンセプトとし、その旨を表示した食品、機能性食品、病者用食品、特定保健用食品に応用できる。さらに、運動不足者や中高年者、ベッドレスト者のみならず、アスリートを含むあらゆる人々に対処するために用いることができる。 Resveratrol and / or grape leaf extract according to the present invention, as shown in the examples below, endurance improvement action, anti-fatigue action, muscle strength improvement action, motor function improvement action, energy metabolism activation action, In addition, it has an aging inhibitory action, specifically, an endurance reduction inhibitory action caused by aging, a muscle atrophy inhibitory action, an energy metabolism lowering inhibitory action, and a muscle strength decline inhibitory action. Therefore, resveratrol and / or grape leaf extract is used for endurance improver, anti-fatigue agent, motor function improver, energy metabolism activator, muscle strength improver and aging inhibitor (hereinafter referred to as “endurance improver etc. And can be used to produce these agents. Endurance improvers, etc. are used as drugs for humans or animals, quasi-drugs, and foods that demonstrate endurance, anti-fatigue, muscle strength, motor function, energy metabolism activation, and anti-aging effects. Is possible. In addition, resveratrol and / or grape leaf extract is based on the concept of endurance improvement, anti-fatigue, motor function improvement, energy metabolism activation, muscle strength improvement or aging suppression in those with exercise deficiency, middle-aged and elderly people, bed rest persons, It can be applied to foods that indicate this, functional foods, foods for the sick, and foods for specified health use. Furthermore, it can be used to cope with not only exercise deficient persons, middle-aged and elderly persons, bed rest persons, but also all people including athletes.
本発明において、「老化抑制」とは、老化に伴い生じる生理的変化を抑制することをいう。当該生理学的変化には、持久力低下、筋萎縮、エネルギー代謝低下、筋力低下が含まれる。 In the present invention, “aging inhibition” refers to inhibiting physiological changes caused by aging. Such physiological changes include decreased endurance, muscle atrophy, decreased energy metabolism, and decreased muscle strength.
本発明の持久力向上剤等を医薬品、医薬部外品として用いる場合の投与形態としては、例えば錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等による経口投与又は注射剤、坐剤、吸入薬、経皮吸収剤、外用剤等による非経口投与が挙げられる。また、このような種々の剤型の製剤を調製するには、本発明のレスベラトロール及び/又はブドウ葉抽出物を単独で、又は他の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、嬌味剤、香料、被膜剤、担体、希釈剤等を適宜組み合わせて用いることができる。また、これらの投与形態のうち、好ましい形態は経口投与であり、経口用液体製剤を調製する場合は、嬌味剤、緩衝剤、安定化剤等を加えて常法により製造することができる。 Examples of the dosage form when the endurance improver of the present invention is used as a pharmaceutical product or quasi-drug include oral administration using tablets, capsules, granules, powders, syrups, etc., or injections, suppositories, and inhalants. And parenteral administration by transdermal absorption agents, external preparations and the like. In order to prepare such various dosage forms, the resveratrol and / or grape leaf extract of the present invention alone or other pharmaceutically acceptable excipients, binders, A bulking agent, a disintegrating agent, a surfactant, a lubricant, a dispersing agent, a buffering agent, a preservative, a flavoring agent, a fragrance, a coating agent, a carrier, a diluent, and the like can be used in appropriate combination. Of these dosage forms, the preferred form is oral administration, and when an oral liquid preparation is prepared, it can be produced by a conventional method by adding a flavoring agent, a buffering agent, a stabilizer and the like.
本発明の持久力向上剤等を食品として用いる場合の形態としては、パン類、ケーキ類、麺類、菓子類、ゼリー類、冷凍食品、アイスクリーム類、乳製品、飲料、スープ類等の各種食品の他、上述した経口投与製剤と同様の形態(錠剤、カプセル剤、シロップ等)が挙げられる。飲料は、例えば、果汁飲料、炭酸飲料、茶系飲料、ニアウオーター、スポーツ飲料、乳飲料、アルコール飲料、清涼飲料等が挙げられる。
種々の形態の食品を調製するには、本発明のレスベラトロール及び/又はブドウ葉抽出物を単独で、又は他の食品材料や、溶剤、軟化剤、油、乳化剤、防腐剤、香科、安定剤、着色剤、酸化防止剤、保湿剤、増粘剤等を適宜組み合わせて持久力向上用食品、筋力向上用食品、運動機能向上用食品、抗疲労用食品、抗老化(アンチエイジング)用食品、ペットフード等として用いることが可能である。
In the case of using the endurance improver of the present invention as food, various foods such as breads, cakes, noodles, confectionery, jelly, frozen foods, ice creams, dairy products, beverages, soups, etc. In addition, the same forms (tablets, capsules, syrups, etc.) as the above-mentioned oral administration preparation are mentioned. Examples of the beverage include fruit juice beverages, carbonated beverages, tea-based beverages, near water, sports beverages, milk beverages, alcoholic beverages, and soft drinks.
To prepare various forms of food, resveratrol and / or grape leaf extract of the present invention alone or other food ingredients, solvents, softeners, oils, emulsifiers, preservatives, fragrances, A combination of stabilizers, colorants, antioxidants, humectants, thickeners, etc., as appropriate, endurance foods, muscle strength foods, motor function foods, anti-fatigue foods, anti-aging products It can be used as food, pet food and the like.
また、本発明の持久力向上剤等は、適当量の栄養補給が困難な高齢者やベッドレスト状態の病者においては、経腸栄養剤等の栄養組成物の形態として用いることが可能である。 In addition, the endurance improver of the present invention can be used as a form of a nutritional composition such as an enteral nutrient in elderly people who are difficult to supplement with an appropriate amount of nutrition or in bed rest. .
これらのものに対するレスベラトロール及び/又はブドウ葉抽出物の配合量は、その使用形態により異なるが、食品の形態では、レスベラトロールは、通常0.0001〜5質量%、さらに0.001〜2質量%、特に0.002〜1質量%とするのが好ましく、ブドウ葉抽出物(乾燥物換算)は、通常0.0001〜10質量%、さらに0.001〜5質量%、特に0.002〜2質量%とするのが好ましい。上記以外の医薬品、例えば錠剤、顆粒剤、カプセル剤等の経口用固形製剤、内服液剤、シロップ剤等の経口用液体製剤の場合には、レスベラトロールは、通常0.01〜95質量%、さらに5〜90質量%、特に10〜50質量%とするのが好ましく、ブドウ葉抽出物(乾燥物換算)は、通常0.01〜95質量%、さらに5〜90質量%、特に10〜50質量%とするのが好ましい。 The compounding amount of resveratrol and / or grape leaf extract with respect to these varies depending on the use form, but in the form of food, resveratrol is usually 0.0001 to 5% by mass, further 0.001 to It is preferable to set it as 2 mass%, especially 0.002-1 mass%, and a grape leaf extract (dry matter conversion) is usually 0.0001-10 mass%, 0.001-5 mass% especially 0.00. It is preferable to set it as 002-2 mass%. In the case of pharmaceutical preparations other than the above, for example, oral solid preparations such as tablets, granules, capsules, and oral liquid preparations such as oral liquids and syrups, resveratrol is usually 0.01 to 95% by mass, Furthermore, it is preferable to set it as 5-90 mass%, especially 10-50 mass%, and a grape leaf extract (dry matter conversion) is 0.01-95 mass% normally, Furthermore, 5-90 mass%, especially 10-50. It is preferable to set it as the mass%.
本発明のレスベラトロール及び/又はブドウ葉抽出物(乾燥物換算)の投与量(有効摂取量)は、一日あたり1〜2000mg/60kg体重とするのが好ましい。このとき、レスベラトロールは、特に3〜700mg/60kg体重、さらに5〜500mg/60kg体重とするのが好ましく、20〜400mg/60kg体重とするのが最も好ましい。また、ブドウ葉抽出物(乾燥物換算)は、特に5〜2000mg/60kg体重、さらに10〜1000mg/60kg体重とするのが好ましく、40〜800mg/60kg体重とするのが最も好ましい。 The dose (effective intake) of resveratrol and / or grape leaf extract (in terms of dry matter) of the present invention is preferably 1 to 2000 mg / 60 kg body weight per day. At this time, resveratrol is particularly preferably 3 to 700 mg / 60 kg body weight, more preferably 5 to 500 mg / 60 kg body weight, and most preferably 20 to 400 mg / 60 kg body weight. The grape leaf extract (in terms of dry matter) is particularly preferably 5 to 2000 mg / 60 kg body weight, more preferably 10 to 1000 mg / 60 kg body weight, and most preferably 40 to 800 mg / 60 kg body weight.
以下に本発明の代表的な試験例と実施例を示す。 The typical test examples and examples of the present invention are shown below.
試験例1 レスベラトロールの持久力向上・抗疲労効果
レスベラトロールの持久力向上・抗疲労効果に対する評価を下記の通り行った。尚、レスベラトロールはCayman社製のものを用いた。
Test Example 1 Resveratrol Endurance Improvement / Anti-Fatigue Effect Evaluation of resveratrol endurance improvement / anti-fatigue effect was performed as follows. Resveratrol manufactured by Cayman was used.
流水プールにおけるマウス限界遊泳時間測定法(参考文献:Am J Physiol Regul Integr Comp Physiol,Vol.288,R708-R715,2005)により、持久力向上・抗疲労効果の評価を行った。実験用プールは、透明なアクリル製のプール(長さ90×幅45×深さ45cm)に38cmの深さまで水を満たし、ヒーターで34℃に維持した状態で使用した。水流はポンプ(C−P60H、日立製)を用いて作り出し、流速はWater flowmeter(東京フローメータ研究所)をポンプに連結させ、バルブの開閉により調節した。また、流速は流速計(SV−101−25S、三光精密工業)で確認を行った。 Endurance improvement and anti-fatigue effects were evaluated by a method for measuring the limit swimming time of mice in a running water pool (reference: Am J Physiol Regul Integr Comp Physiol, Vol. 288, R708-R715, 2005). The experimental pool was used with a transparent acrylic pool (length 90 × width 45 × depth 45 cm) filled with water to a depth of 38 cm and maintained at 34 ° C. with a heater. The water flow was created using a pump (C-P60H, manufactured by Hitachi), and the flow rate was adjusted by connecting a water flow meter (Tokyo Flow Meter Laboratory) to the pump and opening and closing the valve. Moreover, the flow velocity was confirmed with a velocimeter (SV-101-25S, Sanko Precision Industry).
実験動物には5週齢のBalb/c系雄性マウス(チャールスリバー)を用い、一定の飼育環境下(23 ± 2℃、 明期:午前7時から午後7時)で1週間予備飼育をし、馴化を行った。その後1週間は、遊泳運動に慣れさせるためのトレーニングを週3回行った(初日に流速5L/分で30分、3日目、5日目に6L/分で30分の遊泳運動を行った)。次の1週間に、各個体を2時間絶食させた状態で、流速7L/分における限界遊泳時間(呼吸のため水面に顔を出せなくなった状態で救出した時点を限界遊泳時間とした)を2回測定した。限界遊泳時間に群間差が出ないように1群8匹で試験食群と対照食群の2群に群分けを行った。表1に示す配合組成で調製した食餌を用いて10週間飼育を行った。この間、限界遊泳時間測定(7L/分)とトレーニング(6L/分、30分)を週1回ずつ行った。飼育10週目におけるマウスの限界遊泳時間を表2に示した。 As experimental animals, 5-week-old Balb / c male mice (Charles River) were preliminarily raised for 1 week in a constant breeding environment (23 ± 2 ° C, light period: 7 am to 7 pm). Acclimated. After that, for one week, training was performed three times a week to get used to swimming exercise (30 minutes of swimming exercise was performed on the first day for 30 minutes at a flow rate of 5 L / min, 3 days on the third day, and 6 L / min for 30 minutes on the third day). ). In the next week, with each individual fasted for 2 hours, limit swimming time at a flow rate of 7 L / min (the limit swimming time was defined as the time when rescued in a state where the face could not be exposed due to breathing). Measured once. The group was divided into two groups, the test food group and the control food group, with 8 animals per group so that there was no difference between the groups in the limit swimming time. Using the diet prepared with the composition shown in Table 1, the animals were reared for 10 weeks. During this time, limit swimming time measurement (7 L / min) and training (6 L / min, 30 minutes) were performed once a week. Table 2 shows the limit swimming time of mice at the 10th week of breeding.
表2から、レスベラトロールを含有する試験食を摂取したマウスでは、対照食群と比較して10週間飼育後の限界遊泳時間が有意に延長しており、レスベラトロールは持久力向上効果、抗疲労効果を有することがわかる。また、運動機能向上効果を有することがわかる。以上のことからレスベラトロールは持久力向上剤、抗疲労剤、運動機能向上剤として有用である。 From Table 2, in the mice that received the test meal containing resveratrol, the marginal swimming time after 10 weeks of breeding was significantly extended compared to the control group, and resveratrol improved endurance, It can be seen that it has an anti-fatigue effect. Moreover, it turns out that it has a motor function improvement effect. From the above, resveratrol is useful as an endurance improver, anti-fatigue agent, and motor function improver.
試験例2 ブドウ葉抽出物の持久力向上・抗疲労効果
ブドウ葉抽出物及びブドウ種子抽出物の持久力向上・抗疲労効果に対する評価を下記の通り行った。尚、ブドウ葉抽出物は、アスク薬品株式会社の赤ブドウ葉乾燥抽出物を用い、ブドウ種子抽出物はOrganic Herb社のGrape Seed Extract (95%)を用いた。
表3に示す配合組成で調製した食餌以外は、前記試験例1と同様に行った。飼育10週目におけるマウスの限界遊泳時間を表4に示した。
Test Example 2 Endurance Improvement / Anti-fatigue Effect of Grape Leaf Extract Evaluation on the endurance improvement / anti-fatigue effect of the grape leaf extract and grape seed extract was performed as follows. In addition, the grape leaf extract used the red grape leaf dry extract of Ask Pharmaceutical Co., Ltd., and the grape seed extract used Grape Seed Extract (95%) of Organic Herb.
The same procedure as in Test Example 1 was performed except for the diet prepared with the formulation shown in Table 3. Table 4 shows the limit swimming time of mice in the 10th week of breeding.
表4から、赤ブドウ葉抽出物を含有する試験食を摂取したマウスでは、対照食群と比較して10週間飼育後の限界遊泳時間が有意に延長しており、ブドウ葉抽出物は持久力向上効果、抗疲労効果を有することがわかる。また、運動機能向上効果を有することがわかる。一方、ブドウ種子抽出物食を摂取した群においても、対照食群と比較して限界遊泳時間が延長する傾向にあったが、延長の程度はブドウ葉抽出物食群と比較して小さく、有意な差ではなかった。ブドウ葉抽出物とブドウ種子抽出物には、いずれもポリフェノールやアントシアニンなどが含まれているが、今回の試験の結果から、ブドウ葉抽出物に含まれる成分組成が持久力向上剤、抗疲労剤、運動機能向上剤としてより有用であると考えられる。 From Table 4, in the mice that received the test meal containing red grape leaf extract, the marginal swimming time after 10 weeks of breeding was significantly extended compared to the control diet group, and the grape leaf extract was endurance. It can be seen that it has an improving effect and an anti-fatigue effect. Moreover, it turns out that it has a motor function improvement effect. On the other hand, in the group that ingested the grape seed extract diet, the marginal swimming time tended to be extended as compared with the control diet group, but the extent of extension was small compared with the grape leaf extract diet group, which was significant. It was not a big difference. The grape leaf extract and grape seed extract both contain polyphenols and anthocyanins. From the results of this test, the composition of the components contained in the grape leaf extract is an endurance improver and anti-fatigue agent. Therefore, it is considered more useful as a motor function improver.
試験例3 レスベラトロールの老化抑制効果
レスベラトロールの老化に対する評価を下記の通り行った。尚、レスベラトロールはOrganic Herb社製のものを用いた。
Test Example 3 Resveratrol Aging Inhibition Effect Resveratrol was evaluated for aging as follows. Resveratrol was manufactured by Organic Herb.
13週齢のSAM−P1雄性マウス(老化促進モデルマウス)及びSAM−R1雄性マウス(通常老化マウス)を個別飼育にて5週間予備飼育した後、トレッドミル走行に馴化させ、限界走行時間を測定した。マウスをトレッドミル内で安静にし、環境に慣れさせた後に測定を開始した。ベルトの速さは10m/minから始め、10,15m/minで各5分間、20m/minで60分間、22m/minで60分間、24m/minで60分間、26m/minで60分、以降は28m/minの速さで行った。トレッドミル上でマウスが走れなくなった時点を限界走行時間とし、運動持久力を評価した。各系統の限界走行時間に差がないようにSAM−R1対照群、SAM−P1対照群、SAM−P1レスベラトロール群に群分けした(各群5−8匹)。
表5に示す配合で調製した食餌を用いて10週間飼育した。尚,各マウスには15m/minで30分間の運動を週に3回負荷した。
13 weeks old SAM-P1 male mice (aging-promoting model mice) and SAM-R1 male mice (usually aging mice) were preliminarily raised for 5 weeks in individual breeding, then acclimated to treadmill running, and the limit running time was measured did. Measurements were started after the mice were rested in a treadmill and accustomed to the environment. The belt speed starts at 10m / min, 10, 15m / min for 5 minutes each, 20m / min for 60 minutes, 22m / min for 60 minutes, 24m / min for 60 minutes, 26m / min for 60 minutes, and so on Was performed at a speed of 28 m / min. The time when the mouse could not run on the treadmill was defined as the limit running time, and the exercise endurance was evaluated. The SAM-R1 control group, the SAM-P1 control group, and the SAM-P1 resveratrol group were divided into groups (5 to 8 animals) so that there was no difference in the limit running time of each system.
It was reared for 10 weeks using the diet prepared with the formulation shown in Table 5. Each mouse was subjected to exercise for 30 minutes at 15 m / min three times a week.
8週間飼育後に各群の限界走行時間を測定した。この時のマウス限界走行時間を表6に示す。また、9週間飼育後に安静時のエネルギー代謝として各群の酸素消費量を呼気分析により測定した。分析にはOxymaxシステム(コロンバス社)の8連チャンバーを用いた。マウスをチャンバーに入れて6時間安静にした後、24時間、18分毎に2分間連続して測定を行った。24時間の平均酸素消費量を表7に示す。実験最終日にマウスを解剖に供し、腓腹筋、ヒラメ筋、足底筋を摘出した後、重量を測定し、総筋肉重量を求めた。体重当たりの総筋肉重量を表8に示す。 The limit running time of each group was measured after rearing for 8 weeks. Table 6 shows the mouse limit travel time at this time. In addition, after consumption for 9 weeks, oxygen consumption of each group was measured by breath analysis as energy metabolism at rest. For analysis, an 8 chamber chamber of the Oxymax system (Columbus) was used. After the mouse was placed in the chamber and allowed to rest for 6 hours, measurements were taken continuously for 2 minutes every 18 minutes for 24 hours. The average oxygen consumption for 24 hours is shown in Table 7. On the final day of the experiment, the mice were dissected and the gastrocnemius, soleus and plantar muscles were removed, and then the weight was measured to determine the total muscle weight. Table 8 shows the total muscle weight per body weight.
表6の結果から、老化促進マウスであるSAM−P1対照群の限界走行時間は通常老化マウスであるSAM−R1対照群に対して有意に減少しており、老化に伴い持久力は低下するが、レスベラトロールを配合した飼料を摂取したマウスの限界走行時間はSAM−P1対照群に対して有意に長く、レスベラトロールは老化による持久力低下抑制作用を有することがわかる。また、運動機能向上作用を有することがわかる。 From the results of Table 6, the limit running time of the SAM-P1 control group, which is an aging-promoting mouse, is significantly reduced compared to the SAM-R1 control group, which is usually an aging mouse, and the endurance decreases with aging. Moreover, the limit running time of the mouse | mouth which ingested the feed which mix | blended the resveratrol was significantly long with respect to the SAM-P1 control group, and it turns out that resveratrol has the endurance fall inhibitory effect by aging. Moreover, it turns out that it has a motor function improvement effect | action.
表7の結果から、老化促進モデルマウスであるSAM−P1対照群の酸素消費量は通常老化マウスであるSAM−R1対照群に対して有意に減少しており、加齢に伴いエネルギー代謝は低下するが、レスベラトロールを配合した飼料を摂取したマウスの酸素消費量はSAM−P1対照群に対して有意に高く、レスベラトロールは加齢によるエネルギー代謝低下抑制作用を有することがわかる。 From the results of Table 7, the oxygen consumption of the SAM-P1 control group, which is an aging-promoting model mouse, is significantly decreased compared to the SAM-R1 control group, which is a normal aging mouse, and energy metabolism decreases with age. However, the amount of oxygen consumed by mice ingesting a diet containing resveratrol was significantly higher than that of the SAM-P1 control group, indicating that resveratrol has an inhibitory effect on energy metabolism decline due to aging.
表8の結果から、老化促進モデルマウスであるSAM−P1対照群の体重に占める筋肉重量は通常老化マウスであるSAM−R1対照群に対して有意に減少しており、老化に伴い筋肉は萎縮することがわかる。また、レスベラトロールを配合した飼料を摂取したマウスの筋肉重量はSAM−P1対照群に対して有意に大きいことがわかる。
以上のことから、本発明のレスベラトロールは老化抑制剤、具体的には老化に伴う持久力低下抑制剤、筋萎縮抑制剤、エネルギー代謝低下抑制剤として有用である。
From the results in Table 8, the muscle weight in the body weight of the SAM-P1 control group, which is an aging-promoting model mouse, is significantly reduced compared to the SAM-R1 control group, which is usually an aging mouse. I understand that Moreover, it turns out that the muscle weight of the mouse | mouth which ingested the feed which mix | blended resveratrol was significantly larger than the SAM-P1 control group.
From the above, the resveratrol of the present invention is useful as an aging inhibitor, specifically, an endurance reduction inhibitor accompanying aging, a muscle atrophy inhibitor, and an energy metabolism reduction inhibitor.
試験例4 レスベラトロールの老化による筋力低下抑制効果
レスベラトロールの老化による筋力低下に対する評価を下記の通り行った。尚、レスベラトロールはOrganic Herb社製のものを用いた。
Test Example 4 Resveratrol aging effect of muscular strength reduction due to aging Resveratrol was evaluated for muscular strength reduction due to aging as follows. Resveratrol was manufactured by Organic Herb.
13週齢のSAM−P1雄性マウス(老化促進モデルマウス)及びSAM−R1雄性マウス(通常老化マウス)を個別飼育にて5週間予備飼育した後、トレッドミル走行に馴化させた。その後、SAM−R1対照群、SAM−P1対照群、SAM−P1運動群、SAM−P1レスベラトロール群/運動に群分けした(各群5匹)。表9に示す配合で調製した食餌を用いて13週間飼育した。尚,運動群の各マウスには15m/minで30分間の運動を週に3回負荷した。 A 13-week-old SAM-P1 male mouse (an aging-promoting model mouse) and a SAM-R1 male mouse (usually an aging mouse) were preliminarily raised for 5 weeks in individual breeding, and then acclimated to running on a treadmill. Then, it divided into SAM-R1 control group, SAM-P1 control group, SAM-P1 exercise group, SAM-P1 resveratrol group / exercise (each group 5 animals). Using the diet prepared with the formulation shown in Table 9, it was raised for 13 weeks. Each mouse in the exercise group was subjected to exercise at 15 m / min for 30 minutes three times a week.
13週間飼育後にマウスを解剖に供し、摘出した長趾伸筋を37℃のKrebs溶液中(通気条件:95%−酸素,5%−二酸化炭素)で、トランスデューサー(FORT100:World Precision Instruments,Inc.)に固定した。その後、電気刺激(0.5m秒、140Hz)を施し、最大筋力を測定した。筋力の測定結果を表10に示す。 The mice were subjected to dissection after 13 weeks of breeding, and the excised longus extensor muscles were placed in a Krebs solution at 37 ° C. (aeration conditions: 95% -oxygen, 5% -carbon dioxide) with a transducer (FORT100: World Precision Instruments, Inc.). )). Thereafter, electrical stimulation (0.5 ms, 140 Hz) was applied, and the maximum muscle strength was measured. Table 10 shows the measurement results of muscle strength.
表10の結果から、老化促進マウスであるSAM−P1対照群の長趾伸筋の最大筋力は通常老化マウスであるSAM−R1対照群に対して有意に低い値を示し、老化に伴い最大筋力は低下するが、レスベラトロールを配合した飼料を摂取したマウスの最大筋力はSAM−P1対照群に対して有意に高値を示し、レスベラトロールは老化による筋力低下抑制作用を有することがわかる。
以上のことから、本発明のレスベラトロールは老化抑制剤、具体的には老化に伴う筋力低下抑制剤として有用である。
From the results of Table 10, the maximum muscle strength of the long-knee extensor muscle of the SAM-P1 control group, which is an aging-promoting mouse, is significantly lower than that of the SAM-R1 control group, which is usually an aging mouse. However, the maximum muscular strength of mice ingesting a diet containing resveratrol is significantly higher than that of the SAM-P1 control group, and it can be seen that resveratrol has an inhibitory effect on muscular strength reduction due to aging.
From the above, the resveratrol of the present invention is useful as an aging inhibitor, specifically, a muscular strength decrease inhibitor accompanying aging.
製剤例
持久力向上・抗疲労・筋力向上・運動機能向上・エネルギー代謝活性化・筋力向上・老化抑制の各製剤(1)〜(14)を製造した。
(1)果汁飲料
表11に示した配合で、果汁飲料を製造した。
Formulation Examples Each formulation (1) to (14) for improving endurance, anti-fatigue, muscular strength, improving motor function, activating energy metabolism, improving muscular strength, and suppressing aging was produced.
(1) Fruit juice beverage Fruit juice beverage was produced with the formulation shown in Table 11.
(2)カプセル剤
表12に示す組成物(300mg)をカプセル中に封入し、カプセル剤を製造した。
(2) Capsule The composition (300 mg) shown in Table 12 was enclosed in a capsule to produce a capsule.
(3)錠剤
表13に示す組成物(1錠=250mg)を打錠し、錠剤を製造した。
(3) Tablets The composition shown in Table 13 (1 tablet = 250 mg) was tableted to produce tablets.
(4)顆粒剤
表14に示す組成物(1袋=500mg)を混合し顆粒剤を製造した。
(4) Granule The composition shown in Table 14 (1 bag = 500 mg) was mixed to produce a granule.
(5)食品
表15に示す組成物(1錠=1000mg)を打錠し、チュアブルタイプのタブレット食品を製造した。
(5) Food The composition shown in Table 15 (1 tablet = 1000 mg) was tableted to produce a chewable tablet food.
(6)飲料
表16に示す組成物を混合し、飲料を製造した。
(6) Beverage The composition shown in Table 16 was mixed to produce a beverage.
(7)カプセル剤
表17に示す組成物(300mg)をカプセル中に封入し、カプセル剤中を製造した。
(7) Capsule The composition shown in Table 17 (300 mg) was encapsulated in a capsule to produce a capsule.
(8)ゼリー食品
表18に示した配合を65℃で溶解させ、85℃で5分間保持して、殺菌処理後、100mlの容器に分注した。8時間静置して徐冷しながら5℃に冷却して、本発明のレスベラトロールを含有するゼリー食品を調整した。
(8) Jelly food The composition shown in Table 18 was dissolved at 65 ° C., held at 85 ° C. for 5 minutes, sterilized, and dispensed into a 100 ml container. The jelly food containing resveratrol of the present invention was prepared by allowing to stand for 8 hours and cooling to 5 ° C. while gradually cooling.
(9)老化抑制用経腸栄養剤
表19に示した配合で、本発明の老化抑制用経腸栄養剤を常法に従いレトルトパウチ中に封入し、殺菌し、調製した。ミネラル類は、Na、K、Ca、Mg、P、C1、Feなどの有機又は無機塩混合物、ビタミン類は、ビタミンA、D、E、ビタミンB1、B2、B6、B12、C、ナイアシン、パントテン酸などの混合物を、国民栄養所要量に合致した量用いた。
(9) Enteral nutrient for inhibiting aging With the formulation shown in Table 19, the enteral nutrient for inhibiting aging of the present invention was encapsulated in a retort pouch according to a conventional method, sterilized and prepared. Minerals are organic or inorganic salt mixtures such as Na, K, Ca, Mg, P, C1, and Fe. Vitamins are vitamins A, D, E, vitamins B1, B2, B6, B12, C, niacin, pantothene. A mixture of acids, etc. was used in an amount consistent with national nutrition requirements.
(10)果汁飲料
表20に示した配合で、果汁飲料を製造した。
(10) Fruit juice beverage A fruit juice beverage was produced with the formulation shown in Table 20.
(11)カプセル剤
表21に示す組成物(300mg)をカプセル中に封入し、カプセル剤を製造した。
(11) Capsule A composition (300 mg) shown in Table 21 was encapsulated in a capsule to produce a capsule.
(12)錠剤
表22に示す組成物(1錠=250mg)を打錠し、錠剤を製造した。
(12) Tablets The composition shown in Table 22 (1 tablet = 250 mg) was tableted to produce tablets.
(13)食品
表23に示す組成物(1錠=1000mg)を打錠し、チュアブルタイプのタブレット食品を製造した。
(13) Food The composition shown in Table 23 (1 tablet = 1000 mg) was tableted to produce a chewable tablet food.
(14)飲料
表24に示す組成物を混合し、飲料を製造した。
(14) Beverage The composition shown in Table 24 was mixed to produce a beverage.
(14)飲料
表25に示した配合及び条件で、本発明のスポーツ飲料を調製した。本飲料の保存安定性及び風味は良好であった。
(14) Beverage The sports drink of the present invention was prepared with the formulation and conditions shown in Table 25. The storage stability and flavor of this beverage were good.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006272791A JP4739161B2 (en) | 2005-10-26 | 2006-10-04 | Endurance improver |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005311504 | 2005-10-26 | ||
JP2005311504 | 2005-10-26 | ||
JP2006272791A JP4739161B2 (en) | 2005-10-26 | 2006-10-04 | Endurance improver |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007145809A true JP2007145809A (en) | 2007-06-14 |
JP4739161B2 JP4739161B2 (en) | 2011-08-03 |
Family
ID=38207648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006272791A Active JP4739161B2 (en) | 2005-10-26 | 2006-10-04 | Endurance improver |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4739161B2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009234981A (en) * | 2008-03-27 | 2009-10-15 | Shiseido Co Ltd | Food supplement for antiaging, and antiaging agent |
JP2009247254A (en) * | 2008-04-04 | 2009-10-29 | Hosoda Shc:Kk | Health drink |
JP2010024208A (en) * | 2008-07-23 | 2010-02-04 | Shiseido Co Ltd | Ucp2 expression promotor |
JP2010124732A (en) * | 2008-11-26 | 2010-06-10 | Kirin Brewery Co Ltd | Method for producing sparkling liquor having beer taste |
WO2013001786A1 (en) * | 2011-06-29 | 2013-01-03 | 株式会社ロッテ | Eye fatigue suppression composition and food and drink containing same |
WO2013099982A1 (en) | 2011-12-26 | 2013-07-04 | 森永乳業株式会社 | Muscular atrophy preventing agent |
JP2015071583A (en) * | 2013-09-09 | 2015-04-16 | 花王株式会社 | Muscular atrophy inhibitor |
JP2016153427A (en) * | 2016-05-20 | 2016-08-25 | 株式会社山田養蜂場本社 | Anti-aging agent |
KR20170005873A (en) * | 2014-05-27 | 2017-01-16 | 에스에스 세야쿠 가부시키 가이샤 | Oral composition for improving systemic symptoms including sensitivity to cold |
JP2018052982A (en) * | 2017-12-26 | 2018-04-05 | 株式会社山田養蜂場本社 | Anti-aging agent |
JP2018172307A (en) * | 2017-03-31 | 2018-11-08 | 株式会社イムダイン | Fatigue mitigation agent |
JP2019001763A (en) * | 2017-06-19 | 2019-01-10 | 株式会社東洋新薬 | Blood cholesterol rise inhibitory composition |
US10226441B2 (en) | 2014-12-09 | 2019-03-12 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
WO2019116574A1 (en) * | 2017-12-15 | 2019-06-20 | 司 永尾 | Anti-aging health food and cosmetic and method for producing grapeseed-derived anti-aging component |
JP2021016375A (en) * | 2019-07-24 | 2021-02-15 | 日清オイリオグループ株式会社 | Aerobic motor function improver, food composition for aerobic motor function improvement, and pharmaceutical composition for aerobic motor function improvement |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1175708A (en) * | 1997-07-15 | 1999-03-23 | Kikkoman Corp | Protein food |
JPH11318402A (en) * | 1998-05-11 | 1999-11-24 | Kikkoman Corp | Refreshing drinkable preparation |
JP2001008695A (en) * | 1999-06-30 | 2001-01-16 | Mercian Corp | Concentration and recovery of polyphenol and yeast including high concentration of polyphenol |
JP2001069948A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Food for prevention of senescence |
JP2001072582A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
JP2002338464A (en) * | 2001-05-14 | 2002-11-27 | Kikkoman Corp | Muscular atrophy inhibitor |
JP2003334022A (en) * | 2002-05-17 | 2003-11-25 | Toyo Shinyaku:Kk | Endurance-improving food composition |
WO2004112510A1 (en) * | 2003-06-19 | 2004-12-29 | Suntory Limited | Movement physiology improver |
WO2005002672A2 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
JP2005052085A (en) * | 2003-08-05 | 2005-03-03 | Orbis Inc | Food composition |
-
2006
- 2006-10-04 JP JP2006272791A patent/JP4739161B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1175708A (en) * | 1997-07-15 | 1999-03-23 | Kikkoman Corp | Protein food |
JPH11318402A (en) * | 1998-05-11 | 1999-11-24 | Kikkoman Corp | Refreshing drinkable preparation |
JP2001008695A (en) * | 1999-06-30 | 2001-01-16 | Mercian Corp | Concentration and recovery of polyphenol and yeast including high concentration of polyphenol |
JP2001069948A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Food for prevention of senescence |
JP2001072582A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
JP2002338464A (en) * | 2001-05-14 | 2002-11-27 | Kikkoman Corp | Muscular atrophy inhibitor |
JP2003334022A (en) * | 2002-05-17 | 2003-11-25 | Toyo Shinyaku:Kk | Endurance-improving food composition |
WO2004112510A1 (en) * | 2003-06-19 | 2004-12-29 | Suntory Limited | Movement physiology improver |
WO2005002672A2 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
JP2005052085A (en) * | 2003-08-05 | 2005-03-03 | Orbis Inc | Food composition |
Non-Patent Citations (9)
Title |
---|
DARNE, G. ET AL., VITIS, vol. 32, JPN6010071384, 1993, pages 77 - 85, ISSN: 0001804543 * |
HMAMOUCHI, M., FITOTERAPIA, vol. pp.68, JPN6010071383, 1997, pages 332 - 337, ISSN: 0001804542 * |
JASON J. WOOD ET AL., NATURE, vol. 430, JPN6010048010, 2004, pages 686 - 689, ISSN: 0001709075 * |
井上裕康, ビタミン, vol. 78, JPN6010071385, 2004, pages 621 - 623, ISSN: 0001804545 * |
体力科学, vol. 49, no. 6, JPN7010002594, 2000, pages 690, ISSN: 0001901264 * |
体力科学, vol. 50, no. 6, JPN7010002593, 2001, pages 847, ISSN: 0001901263 * |
体力科学, vol. 51, no. 6, JPN7010002595, 2002, pages 640, ISSN: 0001901265 * |
医学のあゆみ, vol. 204, no. 5, JPN7010002596, 2003, pages 309 - 313, ISSN: 0001901266 * |
対応欧州特許出願(欧州特許出願公開第1993522号に対応)に対して平成22年6月17日付けで提出さ, JPN7010004130, ISSN: 0001804544 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009234981A (en) * | 2008-03-27 | 2009-10-15 | Shiseido Co Ltd | Food supplement for antiaging, and antiaging agent |
JP2009247254A (en) * | 2008-04-04 | 2009-10-29 | Hosoda Shc:Kk | Health drink |
JP2010024208A (en) * | 2008-07-23 | 2010-02-04 | Shiseido Co Ltd | Ucp2 expression promotor |
JP2010124732A (en) * | 2008-11-26 | 2010-06-10 | Kirin Brewery Co Ltd | Method for producing sparkling liquor having beer taste |
JP4681038B2 (en) * | 2008-11-26 | 2011-05-11 | 麒麟麦酒株式会社 | Production method of Happoshu |
KR20140048212A (en) | 2011-06-29 | 2014-04-23 | 가부시키가이샤 롯데 | Eye fatigue suppression composition and food and drink containing same |
WO2013001786A1 (en) * | 2011-06-29 | 2013-01-03 | 株式会社ロッテ | Eye fatigue suppression composition and food and drink containing same |
JP2013010714A (en) * | 2011-06-29 | 2013-01-17 | Lotte Co Ltd | Eye fatigue suppressing composition and food and drink including the same |
US9492424B2 (en) | 2011-12-26 | 2016-11-15 | Morinaga Milk Industry Co., Ltd. | Muscle atrophy inhibitor |
WO2013099982A1 (en) | 2011-12-26 | 2013-07-04 | 森永乳業株式会社 | Muscular atrophy preventing agent |
KR20140105860A (en) | 2011-12-26 | 2014-09-02 | 모리나가 뉴교 가부시키가이샤 | Muscular atrophy preventing agent |
JP2015071583A (en) * | 2013-09-09 | 2015-04-16 | 花王株式会社 | Muscular atrophy inhibitor |
US10695392B2 (en) | 2014-05-27 | 2020-06-30 | Ssp Co. Ltd | Oral composition for improving systemic symptoms including sensitivity to cold |
JP2017529314A (en) * | 2014-05-27 | 2017-10-05 | エスエス製薬株式会社 | Oral composition for improving systemic symptoms such as coldness |
KR102395338B1 (en) * | 2014-05-27 | 2022-05-10 | 에스에스 세야쿠 가부시키 가이샤 | Oral composition for improving systemic symptoms including sensitivity to cold |
KR20170005873A (en) * | 2014-05-27 | 2017-01-16 | 에스에스 세야쿠 가부시키 가이샤 | Oral composition for improving systemic symptoms including sensitivity to cold |
US10226441B2 (en) | 2014-12-09 | 2019-03-12 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
JP2016153427A (en) * | 2016-05-20 | 2016-08-25 | 株式会社山田養蜂場本社 | Anti-aging agent |
JP2018172307A (en) * | 2017-03-31 | 2018-11-08 | 株式会社イムダイン | Fatigue mitigation agent |
JP2019001763A (en) * | 2017-06-19 | 2019-01-10 | 株式会社東洋新薬 | Blood cholesterol rise inhibitory composition |
JP7016510B2 (en) | 2017-06-19 | 2022-02-07 | 株式会社東洋新薬 | Blood cholesterol elevation inhibitory composition |
WO2019116574A1 (en) * | 2017-12-15 | 2019-06-20 | 司 永尾 | Anti-aging health food and cosmetic and method for producing grapeseed-derived anti-aging component |
CN111432660A (en) * | 2017-12-15 | 2020-07-17 | 永尾司 | Anti-aging health food and cosmetic and method for producing anti-aging ingredient derived from grape seed |
RU2744299C1 (en) * | 2017-12-15 | 2021-03-05 | Цукаса НАГАО | Therapeutic food products and cosmetic agents for increasing number the of apoptotic cells and for reducing number of necrotic cells and method for producing a component from germinating grape seeds for increasing the number of apoptotic cells and for reducing the number of necrotic cells |
JPWO2019116574A1 (en) * | 2017-12-15 | 2020-04-30 | 司 永尾 | Health foods and cosmetics for increasing the amount of apoptotic cells and decreasing the amount of necrotic cells, and a method for producing a germinated grape seed-derived component for increasing the amount of apoptotic cells and decreasing the amount of necrotic cells |
JP2018052982A (en) * | 2017-12-26 | 2018-04-05 | 株式会社山田養蜂場本社 | Anti-aging agent |
JP2021016375A (en) * | 2019-07-24 | 2021-02-15 | 日清オイリオグループ株式会社 | Aerobic motor function improver, food composition for aerobic motor function improvement, and pharmaceutical composition for aerobic motor function improvement |
Also Published As
Publication number | Publication date |
---|---|
JP4739161B2 (en) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4739161B2 (en) | Endurance improver | |
US20090162457A1 (en) | Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver | |
JP5507802B2 (en) | Muscle aging inhibitor | |
KR20090037403A (en) | Senescence inhibitor | |
JP2011157330A (en) | Motor function improving agent | |
JP2008063318A (en) | Aging inhibitor | |
JP5281268B2 (en) | Strength improver | |
JP2006193435A (en) | Fatigue-improving agent | |
JP2020186205A (en) | Vasodilator | |
RU2670612C9 (en) | Composition for preventing or treating obesity containing a-lipoic acid and n-acetylcysteine as active ingredients | |
KR20130119424A (en) | Ingredients derived from sphaeranthus indicus | |
WO2020091014A1 (en) | Heart rate decreasing agent | |
JP2017070271A (en) | Food product or supplement | |
KR100540498B1 (en) | Hangover curing agent containing astaxanthin and aspartic acid | |
AU2007238938B2 (en) | Compositions comprising pyruvate alkyl esters and uses thereof | |
Al-Okbi et al. | Urgent Need of Nutritional Strategy and Innovated Functional Foods for Athletes Health and Fitness | |
JP7460327B2 (en) | Oral Compositions | |
JP2009023948A (en) | Dopamine-inhibiting agent | |
KR100520985B1 (en) | Hangover curing agent containing astaxanthin and aspartic acid | |
TW201808120A (en) | Agent for improving physical fitness | |
JP4719556B2 (en) | Endurance improver | |
JP2006077027A (en) | Nutritive analeptic and nutritive analeptic drink | |
KR101561139B1 (en) | COMPOSOTIONS COMPRISING α-LIPOIC ACID AND N-ACETYLCYSTEINE FOR PREVENTING OR TREATING OBESITY | |
JP2021050244A (en) | Anti-fatigue agent | |
JP2014051459A (en) | Fat metabolism enhancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110426 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110427 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4739161 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140513 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |